TX-DAVE&BUSTRS/BSTRO-GRP
16.4.2024 15:01:34 CEST | Business Wire | Press release
Dave & Buster's Entertainment, Inc., the ultimate destination for food, drink and entertainment is delighted to announce its latest franchise agreement furthering the brands development in APAC. Dave & Buster’s has finalized a deal to open five new stores in the Philippines, raising the international development store count to 38.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240416173901/en/
Antonio Bautista, Chief International Development Officer of Dave & Buster’s and Paul Manuud, President of The Bistro Group (Photo: Business Wire)
Antonio Bautista, Chief International Development Officer at Dave & Buster’s, stated "We are thrilled to announce our expansion into the Philippines, marking another significant milestone in our global growth strategy. Our partnership with The Bistro Group in the Philippines aligns with our mission to deliver exceptional 'Eat, Drink, Play, and Watch' experiences to a broader audience. The Bistro Group's reputation as a trendsetter in the F&B industry in Southeast Asia and beyond makes them an ideal partner for introducing our brand to the Filipino market."
Paul Manuud, President of The Bistro Group remarks, "We were impressed by Dave & Buster’s holistic offering in the hospitality industry where guests can eat, drink, play and watch sports shows all in one location. It is a very good concept that could pioneer well in the Philippines, being poised to be the first of its kind in the local F & B landscape,” expressing enthusiasm for the partnership, he continued, "Entering the 'eatertainment' sector with a renowned brand is an exciting development for us. This collaboration enhances our portfolio, enabling us to offer unparalleled dining and entertainment experiences in the Philippines."
Dave & Buster's has implemented several strategic initiatives to ensure a successful global expansion, including a customizable footprint tailored to meet specific market requirements and the localization of menu offerings with high regional resonance to cater to local preferences and tastes. They have also introduced a proprietary dynamic pricing model to offer flexible pricing options, launched global marketing programs that are demographically agnostic yet locally executable, and implemented a unique amusement strategy and packages to differentiate themselves in the market.
Dave & Buster's is also excited to offer localized entertainment and late-night programming for customers and introduce immersive experiences to enhance customer engagement in the competitive socializing space. With these initiatives, Dave & Buster's is confident they will provide an exceptional experience to their global customers.
About Dave & Buster’s
Founded in 1982 and headquartered in Coppell, Texas, Dave & Buster's Entertainment, Inc., is the owner and operator of 223 venues in North America that offer premier entertainment and dining experiences to guests through two distinct brands: Dave & Buster’s and Main Event. The Company has 164 Dave & Buster’s branded stores in 42 states, Puerto Rico, and Canada and offers guests the opportunity to "Eat Drink Play & Watch," all in one location. Each store offers a full menu of entrées and appetizers, a complete selection of alcoholic and non-alcoholic beverages, and an extensive assortment of entertainment attractions centered around playing games and watching live sports and other televised events. The Company also operates 59 Main Event branded stores in 20 states across the country, and offers state-of-the-art bowling, laser tag, hundreds of arcade games and virtual reality, making it the perfect place for families to connect and make memories. For more information, visit daveandbusters.com.
About The Bistro Group:
Founded in 1994, The Bistro Group is one of the Philippines’ most progressive restaurant chains that popularized the casual dining concept with the entry of TGIFridays in the country almost 30 years ago. Its success led to the launch of other world-class brands such as Italianni’s, Denny’s, Buffalo Wild Wings, Texas Roadhouse, Randy’s Donuts and Hard Rock Café among others as well as Asian concepts like Watami, Modern Shang, Bulgogi Brothers and Fish & Co. The company owns and operates Bistronomia, a collection of boutique Spanish/Mediterranean restaurants, Las Flores, Rambla, Tomatito, BCN by Las Flores and Rumba. Also part of its portfolio is TBG Elite by award-winning corporate executive chef, Josh Boutwood. Its premier restaurants, highlighted by quality ingredients, seasonality and unique cooking methods are Helm, The Test Kitchen, Savage and Ember. The Bistro Group is driven by a people-focused philosophy that is the backbone of its success. Passion and commitment propel its operations…in every restaurant, behind every dish and with every service rendered with generous hospitality.
For restaurant concepts and more information about The Bistro Group, visit https://www.bistro.com.ph/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240416173901/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom